The pharmacological treatment for uremic restless legs syndrome: Evidence-based review

Movement Disorders

Volumn 25, Issue 10, 2010, Pages 1335-1342

  De Oliveira, Márcio Moysés ^a   Conti, Cristiane Fiquene ^a   Valbuza, Juliana Spelta ^a   De Carvalho, Luciane Bizari Coin ^a   Do Prado, Gilmar Fernandes ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

End stage renal disease; Restless legs syndrome; Systematic review; Uremic

Indexed keywords

ANTICONVULSIVE AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CLONIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; PERGOLIDE;

ACTIMETRY; CLINICAL ASSESSMENT; DIAGNOSTIC ERROR; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; LEG MOVEMENT; OUTCOME ASSESSMENT; POLYSOMNOGRAPHY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP PARAMETERS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; UREMIA;

CROSS-OVER STUDIES; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; EVIDENCE-BASED MEDICINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESTLESS LEGS SYNDROME; UREMIA;

EID: 77954975750     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22955     Document Type: Review

References (42)

1. Ekbom KA. Restless legs syndrome. Neurology 1960;10:868-873.
2. Picchietti D, Winkelman JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005;28:891-898.
3. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292.
4. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-109.
5. American Sleep Disorders Association. The international classification of sleep disorders: diagnostic and coding manual, Revised ed. Rochester, MN: American Sleep Disorders Association. 1997.
6. Takaki J, Nishi T, Nangaku M, et al. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis 2003;41:833-839.
7. Mucsi I, Molnar MZ, Rethelyi J, et al. Sleep disorders and illness intrusiveness in patients on chronic dialysis. Nephrol Dial Transplant 2004;19:1815-1822.
8. Unruh ML, Levey AS, D'Ambrosio C, Fink NE, Powe NR, Meyer KB. Restless legs symptoms among incident dialysis patients: association with lower quality of life and shorter survival. Am J Kidney Dis 2004;43:900-909.
9. Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004;5:309-315.
10. Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease. Am J Kidney Dis 1996;28:372-378.
11. Walker S, Fine A, Kryger MH. Sleep complaints are common in a dialysis unit. Am J Kidney Dis 1995;26:751-756.
12. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome review. Lancet Neurol 2005;4:465-475.
13. Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol 2004;115:1965-1974.
14. Trenkwalder C, Paulus W. Why do restless legs occur at rest?- pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2). Clin Neurophysiol 2004;115:1975-1988.
15. Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003;61:304-309.
16. Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 2004;62:1563-1567.
17. Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-2302.
18. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain 2008;131 (Part 4):902-917.
19. Conti CF, de Oliveira MM, Andriolo RB, et al. Levodopa for idiopathic restless legs syndrome: evidence-based review. Mov Disord 2007;22:1943-1951.
20. Conti CF, de Oliveira MM, Valbuza JS, Prado LB, de Carvalho LB, do Prado GF. Anticonvulsants to treat idiopathic restless legs syndrome: systematic review. Arq Neuropsiquiatr 2008;66:431-435.
21. Molnar MZ, Novak M, Szeifert L, et al. Restless legs syndrome, insomnia, and quality of life after renal transplantation. J Psychosom Res 2007;63:591-597.
22. The International Restless Legs Syndrome Study Group. Validation of The International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
23. Walker SL, Fine A, Kryger MH. L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 1996;19:214-218.
24. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688.
25. Ausserwinkler M, Schmidt P. Successful clonidine treatment of restless leg syndrome in chronic kidney insufficiency. Schweiz Med Wochenschr 1989;119:184-186.
26. Pieta J, Millar T, Zacharias J, Fine A, Kryger M. Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep 1998;21:617-622.
27. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004;43:663-670.
28. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-108.
29. Sandyk R, Bernick C, Lee SM, Stern LZ, Iacono RP, Bamford CR. L-dopa in uremic patients with the restless legs syndrome. Int J Neurosci 1987;35:233-235.
30. Benes H, Kurella B, Kummer J, Kzenwadel J, Selzer R, Kohnen R. Rapid on set of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 1999;22:1073-1081.
31. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-290.
32. Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M. Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail 2004;26:393-397.
33. Miranda M, Fabres L, Kagi M, et al. Treatment of restless legs syndrome in uremic patients undergoing dialysis with pramipexole: preliminary results. Rev Med Chil 2003;131:700-701.
34. Miranda M, Kagi M, Fabres L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology 2004;62:831-832.
35. Pellechia MT, Vitale C, Sabatini M, et al. Ropinerole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 2004;27:178-181.
36. Cavatorta F, Vagge R, Solari P, Queirolo C. Preliminary results with clonidine in the restless legs syndrome in 2 hemodialyzed uremic patients. Minerva Urol Nefrol 1987;39:93.
37. Wetter TC, Trenkwalder C, Stiasny K, et al. Treatment of idiopathic and uremic restless legs syndrome with L-dopa - a double-blind cross-over study. Wien Med Wochenschr 1995;145:525-527.
38. Sakkas GK, Hadjigeorgiou GM, Karatzaferi C, et al. Intradialytic aerobic exercise training ameliorates symptoms of restless legs syndrome and improves functional capacity in patients on hemodialysis: a pilot study. ASAIO J 2008;54:185-190.
39. Zilberman M, Silverberg DS, Schwartz D, Oksenberg A. Restless Legs Syndrome (RLS) in anemic patients with Congestive Heart Failure and Chronic Renal Failure: lack of effect of anemia treatment. Int J Cardiol (in press).
40. Saletu M, Anderer P, Högl B, et al. Acute double-blind, placebo-controlled sleep laboratory and clinical follow up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm 2003;110:611-626.
41. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa levodopa. Sleep 1996;14:629-650.
42. Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-1700.